Skip to Content

BioNJ Announces Keynote Speakers for International BioPartnering Conference on May 10-11, 2012

Dr. Marc Bonnefoi of Sanofi, Peter Kellogg of Merck & Co., Inc., and Dr. Walter Moos of SRI International to Give Keynote Addresses at Third Annual Biopartnering Conference

TRENTON, N.J.--(BUSINESS WIRE)--Apr 26, 2012 - BioNJ, the trade association advocating for New Jersey's thriving biotechnology community, announced today that Marc Bonnefoi, DVM, Ph.D., Head of the Scientific Core Platform Disposition, Safety and Animal Research and Head of the North America R&D Hub at Sanofi; Peter Kellogg, Executive Vice President and CFO at Merck & Co., Inc.; and Walter Moos, Ph.D., Vice President of the Biosciences Division at SRI International will serve as Keynote Speakers at the BioNJ 2012 International BioPartnering Conference.

Held on May 10-11, 2012 at The Westin Princeton at Forrestal Village, the third annual International BioPartnering Conference will attract senior life science executives from global biotech and pharmaceutical companies, the funding community and entrepreneurs from throughout the Eastern U.S., Europe and Asia.

The conference is New Jersey's only biopartnering meeting, giving attendees a unique opportunity to network with industry executives seeking business opportunities, build relationships, discuss possible collaborations, and forge partnerships.

In addition to the Keynote Speakers, the conference will focus on networking events, partnering sessions, company presentations, and panel discussions on topics such as unlocking the potential of tech transfer and an international panel focused on opportunities with Japan.

“Establishing collaborations, partnerships and other close business relationships have become an important aspect of the biotech industry and New Jersey has been witness to an increasing number of successful partnerships and deals between biotech companies and with pharmaceutical and other life science companies over the past five years,” said Debbie Hart, President of BioNJ. “We are thrilled to have Dr. Bonnefoi, Mr. Kellogg, and Dr. Moos share their thoughts on the current and future landscape for collaborations and partnerships within our industry.”

Dr. Bonnefoi will provide the dinner keynote address on Thursday, May 10, discussing “The Transformation of Sanofi as a Global Healthcare Leader.”

At Sanofi, Dr. Bonnefoi heads the Scientific Core Platform Disposition, Safety and Animal Research, which regroups the talents of more than 1,000 associates in China, Europe, Japan and the U.S. to provide Sanofi therapeutic units with quality solutions and expertise in animal research, preclinical and clinical MPK, and preclinical safety from target identification through registration and life-cycle management for small molecules and biological compounds.

Dr. Bonnefoi is also Head of the North America R&D Hub, which includes the R&D activities of Genzyme, Merial, Pharma, and Sanofi Pasteur in the region. The vision of the North America R&D Hub is to provide sustained and unique contributions to the success of global Sanofi R&D by creating a highly innovative and collaborative research environment in the region, and developing productive alliances with external academic and business partners.

Mr. Kellogg will give the luncheon keynote address on Thursday, May 10, in a talk entitled, “Combining our Strengths: New Pathways to Life Science Innovation.”

Mr. Kellogg is the Executive Vice President and CFO of Merck & Co., Inc. with responsibility for Merck's Global Accounting and Controls, Business Planning, Treasury, Tax, Investor Relations and Business Development areas, as well as for coordination of Merck's Internal Audit organization. He joined Merck in his current role in August 2007.

Prior to Merck, Mr. Kellogg served for seven years as the Executive Vice President and CFO of Biogen Idec and the former Biogen, Inc. He oversaw the merger of Biogen, Inc. and the Idec Company in 2003.

Dr. Moos will also speak at a Plenary Session on Thursday with a topic on “Pharmaceutical Innovation, Dollars, and ˜Sense' Research Saves Lives.”

Dr. Moos leads SRI's Biosciences Division, an organization with all of the resources necessary to take research programs from initial discoveries to investigational new drug applications to start human clinical trials. During his career, Dr. Moos has made significant contributions to all stages of drug development, from basic research, through preclinical and clinical development, to the marketplace. Prior to joining SRI in 2005, he was Chairman and CEO of MitoKor (Migenix). Previously, he was a vice president at Chiron (Novartis) and at the Parke-Davis Pharmaceutical Research Division of Warner-Lambert (Pfizer).

In addition to the Keynotes and panels sessions, Jeff Stewart, Associate Practice Executive, Campbell Alliance, will speak on 2012 Partnering Trends & Introduction to Dealmakers' Intention Survey at a morning Plenary Session on May 10, while Dr. Margaret Brennan-Tonetta, Associate Vice President for Economic Development at Rutgers University will address the potential of the recently installed IBM Supercomputer to assist small companies at the Plenary Lunch on May 11.

BioNJ thanks its sponsors including Campbell Alliance, EisnerAmper, LLP, Fisher Scientific, Lowenstein Sandler, Merck and Co. Inc., Merrill DataSite, Ontario Canada, Sanofi and UBIFRANCE.

To register and for additional information, please visit

About BioNJ

BioNJ is singularly focused on advancing the growth and prosperity of New Jersey's biotechnology cluster through advocacy initiatives directed at State and federal public policy issues and networking and educational programs that bring the community together. Founded in 1994 by New Jersey industry CEOs, BioNJ serves as the voice of biotechnology companies located in New Jersey, seeks to promote their economic growth and development and works to encourage new and established companies from around the world to locate to New Jersey. BioNJ represents companies engaged in biopharmaceutical, biomedical, bioagricultural and bioremedial endeavors. To learn more about BioNJ and the International BioPartnering Conference, please visit

Contact: BioNJ
Bill O'Donnell, 609-890-3185
Director of Public Affairs
(C) 609-802-3091


Posted: April 2012